Related Experiment Videos
Antisense therapy for lymphomas
1Molecular Haematology Unit, Institute of Child Health, London, U.K.
Abstract:
The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resistance to chemotherapy in lymphoma and a range of other high BCL-2 expressing malignancies. As additional antisense molecules targeting oncogenes involved in lymphomas become available, it will be possible to combine them with AO to enhance their efficacy, either targeting the same gene at two sites or more a combination of genes (for example, BCL-2 and MYC in Burkitt's lymphoma). Of major importance are approaches to improve AO uptake into cells which is currently poor. Methods to improve antisense uptake into the cell are required and in addition a new generation of oligonucleotides free of the nonspecific thioate toxicities are required. AO are a dramatic new area of research and as such require much evaluation if they are to be applied maximally. Both in vitro and in vivo efficacy has been established. With care, novel therapies based on the biology of the malignant cell may be determined on a scientific basis and may help improve the treatment of patients with these diseases. Gene silencing by antisense oligonucleotides has a role to play as demonstrated in lymphomas.
Insights
Antisense oligonucleotides (AO) show promise for downregulating oncogenes in lymphoma, potentially overcoming chemotherapy resistance. Further research is needed to improve AO delivery and reduce toxicity for enhanced cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Antisense oligonucleotides (AO) offer a potential strategy for targeted gene silencing.
- Oncogenes play a critical role in the development and progression of lymphomas.
- Chemotherapy resistance remains a significant challenge in treating lymphoma and other malignancies.
Purpose of the Study:
- To evaluate the potential of antisense oligonucleotides to downregulate oncogene expression in lymphoma.
- To explore the combination of antisense therapy with chemotherapy to overcome drug resistance.
- To identify strategies for improving AO delivery and reducing associated toxicities.
Main Methods:
- Gene silencing using antisense oligonucleotides targeting oncogenes like BCL-2 and MYC.
- In vitro and in vivo efficacy studies of AO in lymphoma models.
- Investigation of combination therapies involving AO and conventional chemotherapy.
Main Results:
- Antisense oligonucleotides demonstrate the ability to downregulate oncogene expression in lymphomas.
- In vitro and in vivo studies confirm the efficacy of AO.
- Potential for combining AO with chemotherapy to overcome resistance in high BCL-2 expressing malignancies.
Conclusions:
- Antisense oligonucleotides represent a promising therapeutic approach for lymphomas and other cancers.
- Improving AO cellular uptake and developing safer oligonucleotide generations are crucial for clinical application.
- Targeted gene silencing via AO holds potential for improving patient treatment outcomes in malignancies.